Nov 27, 2018· Comment from Association for Accessible Medicines (AAM)· FDA-2018-D-3152-0026
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding Postapproval Changes to Drug Substances; Draft Guidance for Industry. See attached file(s)